A GLP-1 program under $300/month is real in 2026 if you pick a structure that doesn't reset in month two. Four PlexusDx protocols stay under the cap at every published dose tier: Microdose GLP-1 Protocol at $129/mo flat, Semaglutide Injection at $189/mo (or $149/mo on the 6-month plan), Tirzepatide Injection at $289/mo (or $249/mo on the 6-month plan), and GLP-Squared at $289/mo (or $249/mo on the 3-month plan) — all cash-pay, all-inclusive, no membership.

Medicare Part D is statutorily prohibited from covering GLP-1s prescribed solely for weight loss, and manufacturer copay cards are off-limits to Medicare beneficiaries. This guide explains the Medicare GLP-1 Bridge launching July 2026, Part D backdoors for diabetes, CVD, and OSA, and the cash-pay options that work today — including PlexusDx Microdose GLP-1 Protocol at $129/mo flat and Semaglutide Injection at $189/mo month-to-month, or from $149/mo on the 6-month plan.

There is no microdose Zepbound® product. The lowest labeled dose is 2.5 mg a week, and a pen delivers one fixed dose. When people say microdose Zepbound they usually mean staying at 2.5 mg longer, or compounded tirzepatide at a smaller amount, which is not Zepbound®. Here is the difference.

Microdose GLP-1 protocols use lower-than-standard doses of GLP-1 receptor agonists titrated by a clinician for better tolerability. This article covers what microdose means, the rationale, and the PlexusDx Microdose GLP-1 protocol inside the Weight Management Protocols collection.